Moberg Pharma AB (publ) operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Moberg Pharma AB (publ) with three other
pharmaceutical manufacturers in Europe:
sales of 31.14 million Euro [US$36.63 million]
of the United Kingdom
(£19.85 million [US$26.19 million]
of which 100%
was Medical and Scientific Research), and
Horizon Discovery Group PLC
based in the United Kingdom
(£24.07 million [US$31.76 million]
of which 53%
Moberg Pharma AB (publ) reported sales of SEK 334.30 million (US$40.99 million)
December of 2016.
increase of 17.1%
versus 2015, when the company's sales were SEK 285.57 million.
Sales at Moberg Pharma AB (publ) have increased during each of the previous five years
(and since 2011, sales have increased a total of 498%).
Sales of Kerasal saw an increase
that was more than double the company's growth rate: sales were up
120.1% in 2016, from
SEK 31.09 million to SEK 68.41 million.
Moberg Pharma AB (publ) also saw significant increases in sales in
Other Products (up 34.7% to SEK 82.06 million)
Not all segments of Moberg Pharma AB (publ) experienced an increase in sales in 2016:
sales of Divested Products (Jointflex , Fergon , fell 55.2% to SEK 16.32 million.
Moberg Pharma AB (publ) also experienced decreases in sales in
Kerasal Nail /nalox (down 3.7% to SEK 151.29 million)